Amylin (1-37) Human KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY-acid, Disulphide bridge Cys2-Cys7

  • Description

  • Application Data

Description

Peptide hormone deficient inpeoplewith diabetes mellitus; inhibits glucagon secretion and delays gastric emptying

See full description

Application Data

Catalogue number crb1000269
Molecular Weight 3901.85
Sequence (one letter code) KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY-acid, Disulphide bridge Cys2-Cys7
Sequence (three letter code) H-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-OH (Disulphide bridge Cys2-Cys7)
Molecular Weight 3901.85
Purity >85%
References

Singh et al (2015) Role of Cholesterol and Phospholipids in Amylin Misfolding, Aggregation and Etiology of Islet Amyloidosis. Adv. Exp. Med. Biol. 95 PMID: 26149927

Akter et al (2016) Islet Amyloid Polypeptide: Structure, Function, and Pathophysiology. J. Diabetes Res. 2016 1 PMID: 26649319

Data Sheet Material Safety Data Sheet (MSDS)

Amylin, also known as islet amyloid polypeptide (IAPP), is a peptide hormone which is deficient in patients with diabetes mellitus (DM). Amylin is co-secreted with insulin from the pancreatic β-cells. It inhibits glucagon secretion, delays gastric emptying, and thus acts as a satiety agent.  Amylin peptide is capable of forming aggregates, and pancreatic amyloid plaques are present in 90% of patients with DM. Formation of these plaques may be inhibited by insulin via the formation of heteromolecular complexes. Amylin is also involved in adiposity signalling and body weight regulation. 

Amylin is expressed in the human placenta during pregnancy where it may help regulate food intake by both the mother and foetus, and is involved in foetal development of bone, kidneys and pancreas

Amylin (1-37) Human

Cat No.Pack SizePriceQty.
1mg£220.00
0.5mg£170.00
Bulk Quote